Shamburg News · 8-K filed Nov 13, 2026, 8:18 AM EST
Aardvark Therapeutics Reports Third Quarter 2026 Financial Results; FDA Lifts ARD-101 Clinical Hold
AARD · Aardvark Therapeutics, Inc.
- Earnings
- Other event
- Materiality: high
On November 13, 2026, Aardvark Therapeutics reported a third quarter 2026 net loss of $19.2 million, compared with $16.3 million a year earlier, and R&D expenses of $15.7 million. The company reported cash, cash equivalents and short-term investments of $60.3 million as of September 30, 2026, which it said would fund projected operations through 2027. It also disclosed that in October 2026 the FDA lifted the clinical hold on the ARD-101 IND for hyperphagia in Prader-Willi Syndrome and reported exploratory data from the terminated HERO and OLE trials.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-459373.
Written from the filing by Shamburg Markets. Figures are as reported by the company.